Committee 4: workshop on experimental chemotherapy of leprosy.
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use; D002991:Clofazimine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D009166:Mycobacterium leprae / Q000187:drug effects*; D012293:Rifampin / Q000627:therapeutic use; D013421:Sulfamethoxypyridazine / Q000627:therapeutic use
D000995:Antitubercular Agents; D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D013421:Sulfamethoxypyridazine; D012293:Rifampin